Molecular Alterations Associated With Improved Outcome in Patients With Glioblastoma Treated With Tumor-Treating Fields Bookmark

Do molecular biomarkers have any role in treating glioblastoma (GBM)? As outlined in this scientific research report from the academic journal Neuro-Oncology Research Advances, a recent study found that 3 biomarkers were correlated with very great outcome differences for people treated with tumor-treating (electrical) fields.

.

.

Brain Tumor Guide Bookmark

The Musella Foundation has announced online availability of the 12th edition of the Brain Tumor Guide for the Newly Diagnosed.

.

‘Clinically Meaningful’ Improvement in SCLC Patients With Pembrolizumab/Chemo Combo Bookmark

As reported by MedPage Today, long-term results from a clinical trial suggest that a combination of the drug pembrolizumab plus chemotherapy is better than chemo alone for small cell lung cancer (SCLC). But unfortunately, most patients who received the combo did not benefit significantly, and biomarkers are very much needed to identify patients whose cancers will respond well.

.

FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Bookmark

The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.

.

Summary of Kidney Cancer Highlights from ASCO GU 2022 Bookmark

This article from the International Kidney Cancer Coalition (IKCC) outlines updates on treatment options for renal cell carcinoma as presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.

.

Good for Bladder Cancer, Better for Kidney Cancer Bookmark

This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.

.

Recent Advances in Systemic Therapy for Hepatocellular Carcinoma Bookmark

This review article in the academic research journal Biomarker Research discusses how combining immunotherapy and targeted therapies provides new hope for people with hepatocellular carcinoma.

.

Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium Bookmark

In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.

.

Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC Bookmark

As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.

.

Deciphering the Elusive Origin and Pathways of Brain Metastases Bookmark

The most common brain tumors are other types of cancer that have spread (or “metastasized”) to the brain from a primary site elsewhere in the body. And, the genomic makeup of the brain metastases may not be the same as the primary cancer. An article from The ASCO Post discusses what this means for treatment.

.